Teva Takes Aim At First Truvada And Atripla Generics In US

Israeli Firm Set For ‘Some Exclusivity’

 
• By Dean Rudge
  
Generate a summary of this article
Listen to this article
Beta

Teva has secured one of the largest tablet formulation opportunities in the US with the launch of the first generics to Gilead Sciences’ Truvada, including for HIV-1 PrEP, at the same time introducing a version of the triple-combination Atripla. Collectively the brands had sales north of $3bn last year.

Gilead
Teva became the first ANDA sponsor to introduce generics to Gilead's Truvada and Atripla • Source: Shutterstock

Teva has introduced in the US the first generic versions of Gilead Sciences’ linchpin antiretrovirals, the double-combination Truvada (emtricitabine/tenofovir disoproxil) and triple-combination Atripla (emtricitabine/tenofovir disoproxil/efavirenz) tablets, bolstering efforts “for those who are immunocompromised and at risk of developing more severe disease” considering the COVID-19 pandemic.

The Israeli firm’s announced launch was slightly behind a 30 September 2020 launch date provided under a settlement agreement with...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Generics

Amneal Kicks Off China Business With First Approval

Amneal has marked its entry into China after receiving its first product approval in the market. Meanwhile, the firm has also outlined US approvals for two generics currently suffering from shortages.

For Generics, A Victory Lap – And A Warning – On Drug Shortages

Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.

Nichi-Iko Warns Over Delays From Toyama Plant

Nichi-Iko says that remediation activities at its Toyama plant in the wake of a suspension over GMP violations mean that there may be delays to supply.

More from Products

For Generics, A Victory Lap – And A Warning – On Drug Shortages

Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

Biocon And Teva Sign Up To Biosimilars Forum

Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.